Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis

Exclusion Criteria

• •1. current used of biologic, systemic glucocorticoid or immunosuppressive agents; past used of jak inhibitors;
• •2. were pregnant or lactating;
• •3. abnormal findings for patients' complete blood count, liver functions, and kidney function tests;
• •4. presence of any infection or inflammatory; presence of active tumors or an increased risk of tumor complications；
• •5. systemic comorbidities that could interfere with or complicate study assessments.
• •6. those experiencing atopic dermatitis within 6 months were excluded from this study.